BioGend Therapeutics Co., Ltd. announced earnings results for the half year ended June 30, 2019. For the half year, the company announced sales was TWD 566,000 compared to TWD 0 a year ago. Operating loss was TWD 76.004 million compared to TWD 78.158 million a year ago. Net loss was TWD 74.234 million compared to TWD 77.607 million a year ago. Basic loss per share was TWD 0.92 compared to TWD 1.39 a year ago.